Autonomix Medical, Inc. (AMIX)
Autonomix Medical develops precision nerve-sensing catheter systems to detect and modulate peripheral neural signals in disease states. Incorporated in 2014 and based in The Woodlands, Texas, the company went public on NASDAQ in January 2024, raising approximately $11 million at $5 per share before executing a 1-for-20 reverse stock split in October 2024. The firm’s focus is pancreatic cancer pain, chronic pain syndromes, hypertension, and cardiovascular conditions where nerve dysregulation drives pathology.
Microchip-Enabled Sensing Platform
Autonomix’s core technology integrates catheter-delivered microchip arrays capable of detecting peripheral neural electrical activity with spatial resolution sufficient to map disease-relevant nerve pathways. Rather than applying blanket neuromodulation, the system enables physicians to identify and target the specific neural circuits contributing to a patient’s condition. This precision-targeting approach differentiates the company from established pain management competitors like Boston Scientific and Abbott, which predominantly deploy broader stimulation techniques. The intellectual property portfolio encompasses over 80 issued patents and 39 pending applications, including recent European Patent Office grants for cardiac tissue treatment.
Pancreatic Cancer and Chronic Pain
The company’s lead indication addresses a critical unmet need: pain associated with pancreatic cancer, where nerve involvement creates intractable symptoms that limit treatment tolerance and quality of life. Early clinical data suggest potential for opioid-sparing pain control, a significant advancement given epidemic levels of opioid dependence. The modular platform is also being studied in chronic pain, hypertension management via renal denervation, and other cardiovascular applications where autonomic nerve dysregulation plays a disease role.
At a glance
- Development-stage medical device company; NASDAQ listing January 2024
- Proprietary catheter-based microchip sensor arrays for peripheral nerve mapping
- Lead indication: pancreatic cancer pain; secondary focus on chronic pain and cardiovascular conditions
- Patent portfolio: 80+ issued, 39 pending applications
- Reverse stock split (1-for-20) effective October 2024